Verdy Elisabeth, Debrix Isabelle, Benomar Amina, Becker Annie, Flahault Antoine
Service d'hématologie biologique, Paris, Cedex.
Presse Med. 2007 May;36(5 Pt 1):786-93. doi: 10.1016/j.lpm.2006.12.026. Epub 2007 Feb 14.
Heparin-induced thrombocytopenia (HIT) is a serious immune complication of heparin therapy and presents a risk of severe thromboembolic events. Withdrawal of heparin together with administration of an alternative antithrombotic agent is always necessary in patients with suspected HIT. Diagnosis of this complication, however, is often difficult, particularly in hospitalized patients. The aim of this study was to evaluate the impact of multidisciplinary consultation on the appropriate prescription of danaparoid, widely used as an alternative antithrombotic treatment in HIT.
Multidisciplinary consultation between clinician, hematologist, and pharmacist called for reassessment of the HIT diagnosis at day 3 and between day 3 and 10 after the beginning of danaparoid treatment. Continuation or stopping treatment depended on their joint conclusion. All danaparoid prescriptions were evaluated according to this procedure for one year.
HIT was suspected in 26 in-patients. The multidisciplinary approach made it possible to reassess the HIT diagnosis on day 3 and stop the alternative treatment in 42.3% of cases. Danaparoid use decreased by 52% compared with the previous year.
Multidisciplinary consultations between clinician, hematologist, and pharmacist appear useful for minimizing inappropriate prescription of this alternative treatment in cases of suspected HIT.
肝素诱导的血小板减少症(HIT)是肝素治疗的一种严重免疫并发症,存在发生严重血栓栓塞事件的风险。对于疑似HIT的患者,停用肝素并给予替代抗血栓药物总是必要的。然而,这种并发症的诊断往往很困难,尤其是在住院患者中。本研究的目的是评估多学科会诊对达那肝素适当处方的影响,达那肝素在HIT中广泛用作替代抗血栓治疗药物。
临床医生、血液科医生和药剂师之间进行多学科会诊,要求在第3天以及开始使用达那肝素治疗后的第3天至第10天重新评估HIT诊断。治疗的继续或停止取决于他们的共同结论。按照此程序对所有达那肝素处方进行了为期一年的评估。
26名住院患者被怀疑患有HIT。多学科方法使得在第3天重新评估HIT诊断并在42.3%的病例中停止替代治疗成为可能。与上一年相比,达那肝素的使用量减少了52%。
临床医生、血液科医生和药剂师之间的多学科会诊似乎有助于在疑似HIT病例中尽量减少这种替代治疗的不适当处方。